12:00 AM
 | 
Aug 28, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Campath alemtuzumab humanized monoclonal antibody against CD52 regulatory update

Millennium & Ilex Partners, a joint venture between ILXO and MLNM, responded to a June letter from the FDA regarding its 1999 BLA for Campath to treat advanced B cell chronic lymphocytic...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >